Education
About Us
Working with TipRanks
Follow Us
Revelation Biosciences Inc. (REVB)
:REVB
Total Valuation
Revelation Biosciences has a market cap or net worth of $4.39M. The enterprise value is -$3.37M.
Market Cap$4.39M
Enterprise Value-$3.37M
Share Statistics
Revelation Biosciences has 1,699,637 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,699,637
Owned by Insiders3.01%
Owned by Institutions0.51%
Financial Efficiency
Revelation Biosciences’s return on equity (ROE) is -3.19 and return on invested capital (ROIC) is -169.38%.
Return on Equity (ROE)-3.19
Return on Assets (ROA)-2.27
Return on Invested Capital (ROIC)-169.38%
Return on Capital Employed (ROCE)-1.69
Revenue Per Employee0.00
Profits Per Employee-1.88M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Revelation Biosciences is ―. Revelation Biosciences’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value0.81
Price to FCF―
Price to Operating Cash Flow-0.10
PEG Ratio―
Income Statement
In the last 12 months, Revelation Biosciences had revenue of 0.00 and earned -15.04M in profits. Earnings per share was -87.68.
Revenue0.00
Gross Profit-27.92K
Operating Income-7.97M
Pretax Income-15.04M
Net Income-15.04M
EBITDA-7.95M
Earnings Per Share (EPS)-87.68
Cash Flow
In the last 12 months, operating cash flow was -20.23M and capital expenditures 3.00, giving a free cash flow of -25.21M billion.
Operating Cash Flow-20.23M
Free Cash Flow-25.21M
Free Cash Flow per Share-14.83
Dividends & Yields
Revelation Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.45
52-Week Price Change-93.97%
50-Day Moving Average2.58
200-Day Moving Average13.52
Relative Strength Index (RSI)45.74
Average Volume (3m)230.97K
Important Dates
Revelation Biosciences upcoming earnings date is Nov 7, 2025, After Close (Confirmed).
Last Earnings DateAug 8, 2025
Next Earnings DateNov 7, 2025
Ex-Dividend Date―
Financial Position
Revelation Biosciences as a current ratio of 3.43, with Debt / Equity ratio of 0.00%
Current Ratio3.43
Quick Ratio3.43
Debt to Market Cap0.00
Net Debt to EBITDA0.82
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Revelation Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Revelation Biosciences EV to EBITDA ratio is 0.34, with an EV/FCF ratio of 0.15.
EV to Sales0.00
EV to EBITDA0.34
EV to Free Cash Flow0.15
EV to Operating Cash Flow0.15
Balance Sheet
Revelation Biosciences has $5.17M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$5.17M billion.
Cash & Marketable Securities$5.17M
Total Debt$0.00
Net Cash-$5.17M
Net Cash Per Share-$3.04
Tangible Book Value Per Share$27.45
Margins
Gross margin is -30.33%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-30.33%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Revelation Biosciences is $60.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$60.00
Price Target Upside2225.58% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast94.99%